Keyphrases
Heart Failure
100%
Spironolactone
100%
Influence of Age
100%
Americas Region
50%
Age Categories
50%
TOPCAT
50%
Placebo
33%
Heart Failure with Preserved Ejection Fraction (HFpEF)
33%
Estimated Glomerular Filtration Rate
33%
Aging Effect
33%
Confidence Interval
16%
Hazard Ratio
16%
Older Adults
16%
Trial Data
16%
Young Age
16%
Pharmacokinetics
16%
Left Ventricular Ejection Fraction
16%
Heart Failure Hospitalization
16%
Safety Outcomes
16%
Treatment Effect
16%
Patients with Heart Failure
16%
Safety Endpoints
16%
Cardiac Function
16%
All Ages
16%
Natriuretic Peptides
16%
Follow-up Interval
16%
Treatment Safety
16%
Age 50
16%
Composite Outcome
16%
Low Body Mass Index
16%
Aldosterone Antagonists
16%
Older Age Group
16%
TOPCAT Trial
16%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Spironolactone
100%
Placebo
33%
Heart Failure with Preserved Ejection Fraction
33%
Natriuretic Factor
16%
Aldosterone Antagonist
16%
Pharmacokinetics
16%